Cai.O

CAI.O maintains a strong liquidity position, with cash and equivalents amounting to $796.27 million, significantly exceeding its total liabilities of $548.36 million, resulting in a current ratio of 7.85. The company's price-to-book ratio of 9.37 and a debt-to-equity ratio of 0.66 indicate a relatively conservative capital structure.

Profitability metrics reveal a challenging financial position, with a net loss of $68.09 million and a negative return on equity of -11.79%. The operating income of $25.22 million is modest compared to the gross profit of $541.04 million, suggesting high operating expenses or inefficiencies in cost management.

The company's geographic and segment exposure is not explicitly detailed in the available data, but the revenue concentration within the healthcare services and equipment industry implies a high dependency on this sector. This concentration could pose risks in the event of regulatory changes or market downturns in healthcare.

Growth trajectory appears mixed, with a free cash flow of -$446.17 million indicating significant outflows, despite a positive operating cash flow of $83.16 million. The capital expenditure of -$16.26 million suggests a reduction in investment in physical assets, which may affect long-term growth potential.

Risk factors include a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's negative net income and high price-to-book ratio may also signal potential valuation overextension relative to its asset base.

Recent events, including analyst estimates, show a mean price target of $30.46 and a median price target of $30.00, with a mean recommendation of 1.69, indicating a generally positive outlook from analysts. However, the company's current market price of $19.13 is below these targets, suggesting potential for upward movement.

This is the first analysis for Caris Life Sciences Inc (CAI.O), meaning there is no prior basis for computing material changes in the company's profile. Consequently, the synthesis relies on the initial snapshot of the company's structure and recent holder activity rather than comparative deltas. The most significant recent activity involves a major modification in holder positions for investor ID 587. Data detected on June 21, 2026, indicates a reduction in shares held by this investor from 1,635 to 9 shares as of March 31, 2026. This change corresponds to a decrease in the position's value from $0.029 million to $0.000161 million and a drop in portfolio weight from approximately 0.000017% to 0.00000009%. A subsequent signal detected on June 20, 2026, appears to reflect a reversal or correction of this position, showing the share count returning to 1,635 shares with the associated value and weight metrics restored to their previous levels. These rapid, major-severity modifications in the same investor's holding suggest volatility or data reconciliation events in the reporting of this specific stake. Caris Life Sciences Inc currently has 29 top holders but no reported analyst coverage, officer count, or index membership in the available data. The absence of analyst estimates or financials in the cited documents limits the ability to assess broader market sentiment or fundamental performance beyond these specific holder movements.